Prostaglandin E2 and Bradykinin Contribute to Head and Neck Squamous Cell Carcinoma Carcinogenesis Via EGFR Dependent and Independent Mechanisms.

Sufi M. Thomas,Abbey L Wentzel,Qing Zhang,Maria L. Freilino,Daniel C. Chan,William E. Gooding,Jill M. Siegfried,Jennifer R. Granids

2005-01-01

Abstract:169 The epidermal growth factor receptor (EGFR) is upregulated in majority of head and neck squamous cell carcinoma (HNSCC) cell lines and tumors. Overexpression of EGFR increases cellular proliferation and is associated with decreased survival. EGFR inhibitors are currently under clinical investigation for the treatment of several cancers including HNSCC. The anti-tumor efficacies of EGFR inhibitors depend upon several factors including the status of activating mutations of EGFR in tumors. The mechanisms that tumor cells employ to circumvent the effects of EGFR inhibition would be of primary importance in developing novel therapeutic strategies. G-protein-coupled receptors (GPCR) are present on many cell types. Recently others and we have demonstrated that GPCR ligands promote tumor cell growth via activation of the EGFR pathway. In this study we have investigated the effect of GPCR-ligands prostaglandin E2 (PGE2) and bradykinin (BK) on HNSCC tumorigenesis. Both GPCR ligands stimulated growth of HNSCC cells in vitro. In addition an increase in EGFR and MAPK activation was observed by immunoblotting. EGFR-specific tyrosine kinase inhibitors reduced GPCR-ligand-mediated MAPK activation indicating that GPCRs activate MAPK at least in part, via EGFR phosphorylation. Blocking the extracellular domain of EGFR with antibody C225, reduced GPCR-mediated MAPK activation indicating that extracellular ligand binding to the EGFR is required to trigger the EGFR-axis. We further demonstrate that EGFR ligand TGF-α but not HB-EGF is involved in GPCR-mediated EGFR activation and that EGFR ligand release is mediated by matrix metalloproteases. To delineate the pathways triggered by GPCR ligand stimulation independent of EGFR, we downmodulated EGFR with a siRNA approach followed by GPCR ligand stimulation. Activation of MAPK and STAT3 was partially inhibited on EGFR downmodulation. Activation of Akt however was completely abrogated on EGFR siRNA treatment. Thus, GPCR ligands stimulate Akt primarily via EGFR and STAT3 and MAPK via EGFR dependent as well as independent mechanisms. HNSCC cells were tested in cytotoxicity assays for sensitivity to EGFR inhibitor ZD1839 and BK antagonist CU201. HNSCC cells were sensitive to both inhibitors ZD1839 (IC50 of 10 μM) and CU201 (8 μM). Combined blockade of both EGFR and GPCR pathways at low inhibitor concentrations (3μM ZD1839 and 4μM CU201 respectiely) resulted in additive inhibitory effects on HNSCC cell growth compared to either treatment alone. This is consistent with the finding that pathways downstream of both EGFR and GPCR may contribute to HNSCC tumor growth. Combined blockade of both EGFR and GPCRs may be a rational strategy to treat cancers that demonstrate activation of EGFR by GPCRs including HNSCC.